Looking at Dr Henry Querfurth's credentials, he is a leader in the field with 39 years experience and distinguishments in Alzheimers research.
It feels like we have been standing in front of a locked door regarding neurodegenerative diseases and now we are close to finding the key to open the lock. Let's hope that our molecule monepantel is the key to open that door.
The significance of the MND trial cannot be understated. A degree of success will transform current treatments for MND and have a cascade effect to examine treatments of many other neurodegenerative diseases.
Great research as usual kpax. Exciting times ahead!
- Forums
- ASX - By Stock
- PAA
- MND Phase 1/2/3 Trial review what to expect. The Chemistry !
MND Phase 1/2/3 Trial review what to expect. The Chemistry !, page-3
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.65M |
Open | High | Low | Value | Volume |
17.0¢ | 18.0¢ | 17.0¢ | $1.456K | 8.563K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 103011 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 117483 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 103011 | 0.170 |
11 | 173341 | 0.165 |
8 | 332077 | 0.160 |
5 | 572800 | 0.155 |
10 | 378999 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 117483 | 5 |
0.180 | 204837 | 3 |
0.185 | 264496 | 4 |
0.190 | 268528 | 5 |
0.195 | 212632 | 5 |
Last trade - 10.27am 15/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online